Skip to content

Clinical study of aplastic anemia combined with recombinant human thrombopoietin and immunosuppressants in the treatment of severe aplastic anemia aplastic anemia

Clinical study of aplastic anemia combined with recombinant human thrombopoietin and immunosuppressants in the treatment of severe aplastic anemia aplastic anemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056625
Enrollment
Unknown
Registered
2022-02-09
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Aplastic Anemia

Interventions

1:IST+rhTPO+Etrapropa

Sponsors

Henan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age = 4 years old, = 70 years old; 2. ECOG score = 2 (Appendix 2); 3. There are clear blood routine, reticulocyte count, multi-site bone marrow puncture, bone marrow biopsy and other results to diagnose AA; 4. The patient's main tissues and organs function well: 1) Cardiac function: there is no heart disease or coronary heart disease, and the patient's cardiac function is 1-2 (Appendix 3); 2) Liver function: TBIL = 3ULN, AST = 2.5ULN, ALT = 2.5ULN; 3) Renal function: Cr = 1.25ULN; 5. The patient's peripheral superficial venous blood path is smooth, which can meet the requirements of intravenous infusion; 6. There are no other serious diseases (such as autoimmune diseases and immune deficiency) that conflict with this program; 7. History of other malignant tumors.

Exclusion criteria

Exclusion criteria: 1. Suffering from systemic active infection requiring treatment; 2. Those suffering from serious heart, liver, kidney dysfunction and other diseases; 3. HIV-infected patients; 4. Suffering from serious autoimmune diseases or immune deficiency diseases; 5. Severe allergic constitution; 6. Serious mental disorders; 7. Those who have participated in or are currently participating in other clinical trials in the past three months; 8. Previously received standard IST treatment or allogeneic hematopoietic stem cell transplantation.

Design outcomes

Primary

MeasureTime frame
ORR;

Countries

China

Contacts

Public ContactXinjian Liu

Tumor Hospital of Henan Province

liuxinjian0305@126.com+86 15036151966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026